Annalisa Jenkins - 06 Feb 2026 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Director
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
06 Feb 2026
Net transactions value
$0
Form type
4
Filing time
09 Feb 2026, 20:54:28 UTC
Previous filing
13 Jun 2025
Next filing
27 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jenkins Annalisa Director 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO /s/ Kaitlyn Arsenault, as Attorney-in-Fact 09 Feb 2026 0001639481

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +35,000 $0.000000 35,000 06 Feb 2026 Common Stock 35,000 $0.8200 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in equal monthly installments over the one-year period beginning January 19, 2026.